NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Opus Genetics, Inc. IRD
19 fiscal years on record · USD · FY2025 reported · SEC filings only
$-49.6M
Growth
USD 14.2M
Revenue, FY2025 · full 19-year series below
Revenue $M
Net income $M
FY2025 · Revenue 14.2 · Net income -49.6
Compound annual growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−349 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -271.9% · Net -349.3%
ROE
FY2025 · ROE -449.4%
Each USD of equity lost 449 cents this year.
The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · |
| Operating income $B | −0.0 | −0.1 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · |
| EBITDA $B | −0.0 | −0.1 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | · | · | · | · | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · |
| Net income $B | −0.0 | −0.1 | −0.0 | 0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | · | · | · | · | −0.0 | −0.0 | · | · | · | · | · | · | · | · | · | · | · | · |
| EPS, diluted $ | −0.80 | −2.15 | −0.46 | 0.87 | −3.82 | −5.28 | −2.17 | −5.25 | −0.92 | −0.43 | −0.79 | −0.11 | −0.07 | −0.06 | −0.12 | −0.18 | −0.05 | · | · |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −449.4 | −203.2 | −20.8 | 52.3 | −1295.1 | · | · | −190.7 | −149.6 | −51.9 | −63.4 | −94.5 | −85.7 | −61.5 | −107.5 | −183.3 | −252.5 | · | −463.6 |
| Shares out B | 0.07 | 0.03 | 0.02 | 0.02 | 0.02 | 0.01 | 0.00 | 0.00 | 0.03 | 0.02 | 0.20 | 0.18 | 0.15 | 0.12 | 0.10 | 0.08 | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 66 reconciliationsAUDITED
Reconciled in 19 of 19 fiscal years. 29 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007